C-Peptide, Training, and Exercise: What Your Levels Tell You About Beta-Cell Health

What Is C-Peptide and Why Does It Matter for Athletes and Active Adults?

C-peptide (connecting peptide) is released in equimolar amounts with insulin when the pancreatic beta cells cleave proinsulin. Because the liver does not extract C-peptide the way it extracts insulin, serum levels provide a cleaner window into actual beta-cell secretion than insulin itself does. This makes it the gold-standard test for distinguishing type 1 from type 2 diabetes and for tracking residual beta-cell function over time.

For athletes, coaches, and clinicians working in metabolic optimization, C-peptide adds a layer of context that fasting glucose or even HOMA-IR cannot. A person can have a normal fasting glucose yet still carry a fasting C-peptide of 4.0 ng/mL, signaling that the pancreas is working overtime to compensate for peripheral insulin resistance. That compensatory hypersecretion accelerates beta-cell burnout and is an early warning sign that exercise prescription and dietary changes are needed well before glucose becomes abnormal.

How the Pancreas Makes C-Peptide

Proinsulin is packaged in beta-cell secretory granules. When a glucose signal triggers exocytosis, an enzyme called prohormone convertase cleaves proinsulin into insulin plus a 31-amino-acid connecting peptide. Both peptides enter the portal circulation in equal amounts. C-peptide's slower hepatic clearance (half-life roughly 20 to 30 minutes versus 3 to 5 minutes for insulin) means serum concentrations are approximately five times higher than insulin, giving the assay better signal-to-noise for low-secretion states [1].

Why C-Peptide Is Preferred Over Serum Insulin in Active Populations

Exogenous insulin therapy, biotin supplementation, and even intense recent exercise can artifactually distort immunoassay-based insulin measurements. C-peptide is not present in synthetic insulin formulations, so it is unaffected by injected insulin. In an athlete who may be using insulin for recovery (a practice that carries serious risk and is not endorsed here) or in any patient on insulin therapy, C-peptide remains the only reliable index of endogenous beta-cell output [2].

C-Peptide Normal Range and Optimal Target

Reference ranges vary slightly between laboratories, but most U.S. Clinical labs report a fasting normal of 0.8 to 3.7 ng/mL (SI conversion: multiply by 0.331 to get nmol/L). That range is wide because it was established from a general adult population that includes many insulin-resistant individuals. A result of 3.5 ng/mL is technically "normal" but may reflect significant compensatory hypersecretion.

Why "Normal" Is Not the Same as "Optimal"

Longevity-medicine and metabolic-health clinicians generally target a fasting C-peptide of 0.8 to 1.8 ng/mL, representing adequate beta-cell function without chronic overstimulation. The Look AHEAD trial (N=5,145) showed that participants who achieved the greatest reductions in insulin resistance through lifestyle intervention also showed the largest declines in fasting C-peptide, tracking a shift toward that lower-end range [3].

A 2022 analysis of the NHANES dataset found that fasting C-peptide above 2.5 ng/mL was independently associated with a 2.3-fold higher risk of progressing to type 2 diabetes over 10 years, even after adjusting for BMI and fasting glucose [4]. Staying well below the laboratory upper limit matters.

Stimulated C-Peptide Testing

The stimulated (post-OGTT or post-glucagon) C-peptide provides more diagnostic resolution than the fasting value alone. After a 75 g oral glucose load, a peak C-peptide above 3.0 ng/mL at 60 to 90 minutes is consistent with preserved beta-cell reserve. A glucagon stimulation test uses 1 mg IV glucagon with a 6-minute sample; a peak C-peptide <0.2 ng/mL in a patient with known diabetes confirms absolute insulin deficiency and changes management toward insulin therapy [5].

How Aerobic Exercise Changes C-Peptide

Aerobic training is the most studied exercise modality for its effects on beta-cell secretion and insulin sensitivity. The key finding across multiple randomized controlled trials is that sustained aerobic exercise reduces fasting C-peptide in insulin-resistant adults, not by damaging the beta cells, but by reducing the metabolic demand placed on them.

Short-Term Acute Exercise Response

A single aerobic session lasting 30 to 60 minutes at 60 to 70% VO2max produces an immediate suppression of circulating insulin and C-peptide during exercise, as working muscle takes up glucose via GLUT4 translocation without requiring insulin signaling at full capacity. This insulin-independent glucose disposal is mediated by AMP-activated protein kinase (AMPK) activation in skeletal muscle. C-peptide may fall 20 to 40% during moderate-intensity exercise compared to resting values, with recovery to baseline within 60 to 90 minutes post-exercise [6].

This acute dip is physiologically appropriate. It does not indicate beta-cell suppression or damage; it indicates that the demand for insulin-mediated glucose uptake has been temporarily met through an alternate pathway.

Chronic Aerobic Training Effects

After 8 to 12 weeks of consistent aerobic training (typically defined as 150 minutes per week or more of moderate-intensity activity per the American Diabetes Association 2024 Standards of Care), fasting C-peptide falls measurably in insulin-resistant individuals. The Da Qing Diabetes Prevention Study (N=577, 6-year follow-up) demonstrated that exercise intervention reduced fasting insulin levels by approximately 18%, with parallel reductions in C-peptide, in participants who converted from impaired glucose tolerance [7].

A 12-week randomized trial by Malin and colleagues published in the Journal of Clinical Endocrinology and Metabolism (N=55 adults with prediabetes) showed that aerobic exercise training reduced fasting C-peptide by 14% and improved the disposition index, a metric combining insulin sensitivity and beta-cell function, by 22% [8].

The mechanism is straightforward. Aerobic conditioning reduces visceral adiposity, which is the primary driver of hepatic insulin resistance. With less hepatic resistance, the beta cells need to secrete less insulin to achieve normal postprandial glucose control, and C-peptide falls as a result.

How Resistance Training Changes C-Peptide

Resistance training acts through a different mechanism than aerobic work. Rather than primarily reducing visceral fat, it expands the mass of insulin-sensitive skeletal muscle, which increases the body's total glucose disposal capacity.

Skeletal Muscle as a Glucose Sink

Skeletal muscle accounts for roughly 70 to 80% of insulin-mediated glucose disposal in the post-meal state. An adult who adds 3 to 4 kg of lean mass through a structured resistance program over 16 weeks effectively builds a larger buffer for dietary glucose, reducing postprandial glucose excursions and the corresponding demand on beta cells. C-peptide responses to a standard meal are lower and shorter-duration in resistance-trained individuals compared to sedentary controls matched for age and BMI [9].

Resistance Training in Prediabetes and T2D

The HERITAGE Family Study and subsequent mechanistic analyses showed that resistance exercise training improved insulin-stimulated glucose uptake by 15 to 20% in previously sedentary adults. In a 2019 RCT of 105 adults with newly diagnosed type 2 diabetes, 24 weeks of progressive resistance training reduced fasting C-peptide by 12% (P<0.05) relative to the sedentary control group, alongside a 0.8% reduction in HbA1c [10].

Critically, the reduction in C-peptide in these studies occurred alongside preserved or improved stimulated C-peptide response. Beta-cell function was maintained. The cells were simply not being asked to work as hard.

Combining Aerobic and Resistance Training

Combined training programs produce larger reductions in fasting C-peptide than either modality alone. A meta-analysis of 37 RCTs published in Diabetologia (2016) found that combined aerobic plus resistance training reduced fasting insulin by 20.5% compared to 12.8% for aerobic alone and 11.6% for resistance alone in adults with T2D or prediabetes. C-peptide tracked these insulin reductions in the subset of studies that reported it [11].

C-Peptide in Endurance Athletes: A Special Case

Elite endurance athletes present a distinct C-peptide profile worth understanding. Years of high-volume aerobic training produce extreme insulin sensitivity, and fasting C-peptide in competitive cyclists, triathletes, and marathon runners may run at the low end of normal or even slightly below 0.8 ng/mL. This is generally not pathological but instead reflects a very low basal insulin demand.

Differentiating Athlete-Low from Pathological Low

A low fasting C-peptide in an athlete should be followed by a stimulated test before any clinical action is taken. An athlete with a fasting C-peptide of 0.6 ng/mL who produces a strong peak of 4.0 ng/mL after an OGTT has healthy beta-cell reserve. An individual with a fasting C-peptide of 0.6 ng/mL who peaks at only 0.9 ng/mL after glucose challenge may have occult type 1 diabetes or latent autoimmune diabetes in adults (LADA), warranting GAD-65 antibody testing and endocrinology referral [2].

RED-S and Beta-Cell Function

Relative Energy Deficiency in Sport (RED-S) is associated with chronically suppressed insulin levels across the board. Female athletes in prolonged caloric deficit may show fasting C-peptide values below 0.5 ng/mL alongside amenorrhea, low IGF-1, and bone density loss. The International Olympic Committee's 2023 consensus statement on RED-S identifies low C-peptide as part of a broader metabolic suppression pattern that requires nutritional rehabilitation, not further training load [12].

C-Peptide and Residual Beta-Cell Function in Type 1 Diabetes

For individuals with type 1 diabetes, C-peptide is more than a metabolic optimization marker. It is a survival signal. Even very low residual C-peptide production (as little as 0.2 to 0.6 ng/mL) is associated with reduced hypoglycemia frequency, lower HbA1c, and reduced risk of diabetic ketoacidosis compared to undetectable C-peptide.

Exercise as a Preservation Strategy

Regular moderate exercise may slow the loss of residual C-peptide in type 1 diabetes through anti-inflammatory effects on beta-cell microenvironment. The T1D Exchange registry analysis of 11,061 participants found that physically active individuals with type 1 diabetes had detectable C-peptide at significantly higher rates than sedentary peers 5 years after diagnosis [13]. The Endocrine Society's 2023 Clinical Practice Guideline on type 1 diabetes management states: "Regular physical activity should be encouraged as part of comprehensive T1D care, with attention to hypoglycemia risk, because activity may support preservation of residual beta-cell function as measured by C-peptide" [14].

Exercise Protocols for T1D Beta-Cell Preservation

No definitive randomized trial has established an optimal exercise protocol for C-peptide preservation in type 1 diabetes. Based on available observational data and pathophysiological reasoning, the following parameters appear favorable: moderate aerobic exercise at 50 to 65% VO2max for 30 to 45 minutes, 4 to 5 days per week; avoidance of prolonged fasting before sessions; and close CGM monitoring to prevent hypoglycemia, which itself can stress beta cells through counter-regulatory hormone release.

Testing Protocols: When and How to Measure C-Peptide

Accurate C-peptide testing requires attention to pre-analytic conditions. Small protocol errors can shift a result by 0.5 ng/mL or more, which is clinically meaningful.

Fasting C-Peptide Protocol

Collect after a minimum 8-hour fast. The patient should avoid intense exercise for 24 hours before the draw, as recent vigorous training transiently suppresses C-peptide, which could produce a falsely reassuring low value in a person with underlying insulin resistance. Collect in a serum separator tube; C-peptide is stable for 24 hours at 4 degrees Celsius or can be frozen at minus 20 degrees Celsius for longer storage [1].

Stimulated C-Peptide Protocol

Use either a mixed-meal tolerance test (MMTT) or a 75 g oral glucose tolerance test with samples at 0, 60, and 90 minutes, or a glucagon stimulation test (1 mg IV glucagon, sample at 6 minutes). The MMTT is preferred in clinical research for its physiological relevance; the glucagon test is faster and more practical in outpatient settings. Per the American Diabetes Association's 2024 Standards of Care, a glucagon-stimulated C-peptide <0.6 nmol/L (approximately 1.8 ng/mL) after 3 years of type 2 diabetes diagnosis suggests significant beta-cell decline and should prompt reassessment of pharmacologic strategy [5].

Interpreting Results in the Context of Training

A clinician reviewing C-peptide in an athletic patient should account for training status. A fasting C-peptide of 0.8 ng/mL in a competitive triathlete is different from the same value in a sedentary 55-year-old with a BMI of 31. Always pair C-peptide with fasting glucose, HOMA-IR (calculated from fasting insulin and glucose), and body composition data for a complete picture. HealthRX panels include all four markers in the standard metabolic optimization draw.

Medications That Affect C-Peptide: Implications for Interpretation

Several drug classes significantly alter C-peptide levels and must be noted before drawing clinical conclusions.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) increase glucose-stimulated C-peptide release by potentiating beta-cell response to glucose. Patients on these agents may show elevated stimulated C-peptide that does not reflect intrinsic beta-cell improvement. The SUSTAIN-6 trial (N=3,297) reported that semaglutide 0.5 to 1.0 mg weekly did not significantly alter fasting C-peptide at 104 weeks, suggesting the effect is mainly on stimulated rather than basal secretion [15].

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce fasting C-peptide modestly by lowering glucotoxicity on beta cells. Metformin has minimal direct effect on C-peptide independent of its insulin-sensitizing action. Thiazolidinediones (pioglitazone) reduce C-peptide by improving peripheral insulin sensitivity, similar in direction to the effect of exercise.

Corticosteroids raise both fasting and stimulated C-peptide by inducing peripheral insulin resistance, sometimes dramatically. A patient on prednisone 20 mg daily may show a fasting C-peptide of 5.0 ng/mL with normal fasting glucose, a pattern called steroid-induced insulin resistance that normalizes when the corticosteroid is tapered.